Please login to the form below

Not currently logged in

AZ drug for opioid constipation starts FDA review

Naloxegol on course to compete with Takeda’s Amitiza
AstraZeneca AZ headquarters London UK

AstraZeneca (AZ) took a step closer to securing US approval for its new candidate for opioid drug-induced constipation (OIC) after the US Food and Drug Administration (FDA) started the clock ticking on its review of the drug.

Naloxegol - a pegylated form of opioid antagonist naloxol licensed from US firm Nektar Therapeutics - could become the first once-daily drug in its class for OIC in the US, setting it up to compete with Sucampo and Takeda's twice-daily Amitiza (lubiprostone).

It is estimated that around 35 million patients taking opioids for long-term pain relief develop constipation, with 40 to 50 per cent failing to get relief from current therapies. This has led to peak sales estimates of $350m or more per year at peak, while some analysts suggest even $1bn-plus is feasible. 

Sucampo reported Amitiza sales of a little over $80m in 2012 but that product is also tipped to reach $200m.

In two phase III trials, the highest dose of naloxegol tested (25mg) achieved significant increases in spontaneous bowel movement frequency compared to placebo, although a lower 12.5mg dose achieved that objective in only one of the pivotal studies.

There were few cardiovascular side effects reported - which could be significant as the FDA raised concerns about heart effects in patients who use opioids for chronic pain alongside OIC drugs on a long-term basis.

The acceptance of the marketing application by the FDA sparks a $70m milestone payment to Nektar. The biotech also stands to get an additional $140m in milestone payments upon approval and launch in the US and EU. An FDA advisory panel has been tentatively scheduled for March 10-11, 2014.

Naloxegol was the first oral drug designed using Nektar's polymer conjugate technology and has been engineered to stay out of the central nervous system (CNS) to preserve the painkilling effects of the opioids, while antagonising the mu-opioid receptors in the gut to reverse the constipating  side effect.

Article by
Phil Taylor

20th November 2013

From: Sales



Featured jobs

Subscribe to our email news alerts


Add my company
Research Partnership

We are the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the global pharmaceutical...

Latest intelligence

Is China ready for a pharmaceutical gold rush?
Some describe doing business in China as akin to the 1990s internet boom – so how stable is its future?...
AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...